Skip to main content

23andMe gets FDA clearance for prostate cancer risk test

23andMe gets FDA clearance for prostate cancer risk test


It’s the third cancer risk test from the company

Share this story

If you buy something from a Verge link, Vox Media may earn a commission. See our ethics statement.

Photo by Smith Collection/Gado/Getty Images

Genetics testing company 23andMe received Food and Drug Administration clearance for its prostate cancer risk test, the company announced today. It’s 23andMe’s third clearance for a cancer risk report — the company also has tests for genes that predict breast and colorectal cancer risk.

The test screens for a specific mutation on the HOXB13 gene linked with an increased risk of developing prostate cancer. Men with the mutation, the G84E variant, have around a three-fold higher chance of developing prostate cancer than men without, one study found. Around one in 70 people of European descent have the variant, according to a statement from 23andMe.

The prostate cancer risk report is not yet available to 23andMe customers, the company said. Customers will be able to choose whether or not they want to see their results. Those that choose to see it will also get access to an “educational module” to give them information about how to interpret the results.

23andMe received its first FDA sign-off for a cancer risk screening test in 2018, when the agency cleared its tests for three mutations on the BRCA1 and BRCA2 genes. The mutations are associated with higher risk for prostate cancer, ovarian cancer, and breast cancer. However, those specific mutations aren’t the most common mutations linked to those cancers in the general population — they’re most common among people of Ashkenazi Jewish ancestry. They can offer some information to 23andMe customers but can’t rule out other mutations that are also linked to those cancers.

The company’s test for genetic variants linked to a hereditary colorectal cancer syndrome was cleared by the FDA in early 2019. That specific type of cancer only accounts for around 5 percent of colorectal cancers.

“These reports provide our customers with the knowledge that they might be at risk for certain diseases, including hereditary cancers, empowering them to take appropriate preventative action with their healthcare provider,” Anne Wojcicki, CEO and co-founder of 23andMe, said in a statement about the new prostate cancer test.

After initial tussles with the FDA over its attempts to give people health information based on their genetic code, 23andMe is building a portfolio of medical tools. Along with its three cancer risk tests, the company gives customers information on their risk of developing other health conditions and how their bodies might process medications. It’s also developed drugs using its database of genetic information on millions of people.

The company went public via a special purpose acquisition company (SPAC) in February 2021.